For the quarter ending 2025-09-30, OLMA made $49,537K in revenue. -$42,217K in net income. Net profit margin of -85.22%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 39,951 | 43,902 | ||
| General and administrative | 5,926 | 3,962 | ||
| Total operating expenses | 45,877 | 47,864 | ||
| Loss from operations | -45,877 | -47,864 | ||
| Interest income | 3,648 | 4,042 | ||
| Other income | 12 | 38 | ||
| Total other income | 3,660 | 4,080 | ||
| Net loss | -42,217 | -43,784 | ||
| Net loss per share, basic (in dollars per share) | -0.49 | -0.51 | ||
| Net loss per share, diluted (in dollars per share) | -0.49 | -0.51 | ||
| Weighted average shares used to compute net loss per share, basic (in shares) | 85,732,221 | 85,497,426 | ||
| Weighted average shares used to compute net loss per share, diluted (in shares) | 85,732,221 | 85,497,426 | ||
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)